Correspondence 0000950170-24-019942 from Lite Strategy, Inc. (LITS)
Lite Strategy, Inc.
Date: Feb. 26, 2024 · CIK: 0001262104 · Accession: 0000950170-24-019942
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-277201
Letter
Re: MEI Pharma, Inc.
February 26, 2024
VIA EDGAR TRANSMISSION
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: Office of Life Sciences
Registration Statement on Form S-3
Filed February 20, 2024
File No. 333-277201
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, MEI Pharma, Inc. (the “Company”) hereby requests acceleration of the effective date of its Registration Statement on Form S-3 (File No. 333-277201), so that such registration statement may become effective at 2:00 p.m. (Washington, D.C. time) on February 28, 2024, or as soon as practicable thereafter.
MEI PHARMA, INC.
By:
/s/ Justin J. File
Name:
Justin J. File
Title:
Chief Financial Officer
Show Raw Text
CORRESP
1
filename1.htm
CORRESP
February 26, 2024
VIA EDGAR TRANSMISSION
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: Office of Life Sciences
Re: MEI Pharma, Inc.
Registration Statement on Form S-3
Filed February 20, 2024
File No. 333-277201
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, MEI Pharma, Inc. (the “Company”) hereby requests acceleration of the effective date of its Registration Statement on Form S-3 (File No. 333-277201), so that such registration statement may become effective at 2:00 p.m. (Washington, D.C. time) on February 28, 2024, or as soon as practicable thereafter.
MEI PHARMA, INC.
By:
/s/ Justin J. File
Name:
Justin J. File
Title:
Chief Financial Officer